Description
Pralsetinib
Each LuciPral capsule contains: Pralsetinib … 100mg
INDICATION
LuciPral is a kinase inhibitor indicated for treatment of: 1) Adult patients with metastatic rearranged during transfection (RET) fusionpositive non-small cell lung cancer as detected by an FDA approved test (NSCLC). 2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET- mutant medullary thyroid cancer (MTC) who require systemic therapy 1. 3) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion -positive thyroid cancer who require systemic therapy and who are radioactive iodine- refractory
DOSAGE AND USE
The recommended dosage in adults and pediatric patients 12 years and older is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking LuciPral). The capsule should be swallowed whole & not chewed or crushed.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of the reach of Children. Do not administered Luci Pral in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.